Publications de l'équipe Levure Modèle de Pathologies Humaines
Publications par année
2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003 / 2002 / 2001 / 2000 / 1999 / 1997 / 1996
- Wilson JB*, Manet E*, Gruffat H*, Busson P*, Blondel M*, Fahraeus R* (2018) EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against EBV-Associated Cancers. Cancers 10(4): 109 *contributed equally.
- Carmona-Gutierrez D, Bauer MA, Zimmermann A, Aguilera A, Austriaco N, Ayscough K, Balzan R, Bar-Nun S, Barrientos A, Belenky P, Blondel M, et al (2018) Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell 5(1): 4-31
- Panozzo C, Laleve A, Tribouillard-Tanvier D, Ostojić J, Sellem CH, Friocourt G, Bourand-Plantefol A, Burg A, Delahodde A, Blondel M, Dujardin G (2017). Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. Biochim Biophys Acta Molecular Cell Research. 1864(12): 2297-2307.
- Billant O, Blondel M, Voisset C. (2017). p53, p63 and p73 in the wonderland of S. cerevisiae. Oncotarget. 8(34): 57855-57869.
- Lista MJ, Martins RP, Angrand G, Quillévéré A, Daskalogianni C, Voisset C, Teulade-Fichou MP, Fåhraeus R, Blondel M. (2017). A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness. Microb Cell. 4(9): 305-307.
- Lista MJ, Martins RP, Billant O, Contesse MA, Findakly S, Pochard P, Daskalogianni C, Beauvineau C, Guetta C, Jamin C, Teulade-Fichou MP, Fåhraeus R, Voisset C*, Blondel M* (2017). Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA. Nat Commun. 8: 16043.
- Voisset C, Blondel M, Jones GW, Friocourt G, Stahl G, Chédin S, Béringue V, Gillet R. (2017). The double life of the ribosome: When its protein folding activity supports prion propagation. Prion. 11(2): 89-97.
- Billant O, Léon A, Le Guellec S, Friocourt G, Blondel M, Voisset C (2016). The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget doi: 10.18632/oncotarget.11774
- Blondel M, Soubigou F, Evrard J, Nguyen PH, Hasin N, Chédin S, Gillet R, Contesse MA, Friocourt G, Stahl G, Jones GW, Voisset C (2016). Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. Sci. Rep. 6, 32117.
- Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, Nylander K, Voisset C, Blondel M, Fåhraeus R (2015). Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. J Pathol 235(2):334-41.
- Lasserre JP, Dautant A, Aiyar RS, Kucharczyk R, Glatigny A, Tribouillard-Tanvier D, Rytka J, Blondel M, Skoczen N, Reynier P, Pitayu L, Rötig A, Delahodde A, Steinmetz LM, Dujardin G, Procaccio V, di Rago JP (2015). Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. Dis Model Mech 8(6):509-526.
- Lista MJ, Voisset C, Contesse MA, Friocourt G, Daskalogianni C, Bihel F, Fåhraeus R, Blondel M (2015).The long-lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein-Barr virus. Biotechnol J. 10(11):1670–1681.
- Voisset C, Blondel M. (2014) Chemobiology at happy hour: yeast as a model for pharmacological screening. Med Sci (Paris). 30(12):1161-1168
- Aiyar RS, Bohnert M, Duvezin-Caubet S, Voisset C, Gagneur J, Fritsch ES, Couplan E, von der Malsburg K, Funaya C, Soubigou F, Courtin F, Suresh S, Kucharczyk R, Evrard J, Antony C, St Onge RP, Blondel M, di Rago JP, van der Laan M, Steinmetz LM. (2014). Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat Commun. 5:5585
- Montier T, Pichon C, Blondel M, Midoux P. (2014). Editorial: Current status and prospects on nucleic acid transfer. Biotechnol J. 9(11):1363-4
- Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Beringue V, Blondel M, Bihel F, Voisset C. (2014). Structure-Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost α2-Adrenergic Receptor Agonistic Activity. ACS Chem Neurosci. 5(10):1075-82.
- Voisset C, Daskalogianni C, Contesse MA, Mazars A, Arbach H, Le Cann M, Soubigou F, Apcher S, Fåhraeus R, Blondel M (2014). A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion. Dis Model Mech. 7:435-44
- Nguyen PH, Oumata N, Soubigou F, Evrard J, Desban N, Lemoine P, Bouaziz S, Galons H, Blondel M and Voisset C (2014). Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. European Journal of Medicinal Chemistry. 82:363-37
- Voisset C, García-Rodríguez N, Birkmire A, Blondel M, Wellinger RE (2014). Using yeast to model calcium-related diseases: Example of the Hailey-Hailey disease. Biochim Biophys Acta, Molecular Cell Research 1843:2315–2321
- Morris MC, Blondel M (2014). Meeting report: 3(rd) Meeting of the Biosensor Workgroup of the GDR2588. Biotechnol J 9(2):178-9.
- Morris MC, Blondel M (2014). Editorial: Fluorescent biosensors. Biotechnol J. 9(2):171-3.
- Pang Y, Kurella S, Voisset C, Samanta D, Banerjee D, Schabe A, Das Gupta C, Galons H, Blondel M, Sanyal S (2013). The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. J Biol Chem 288(26):19081-9
- Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C (2013). The Toll-Like Receptor Agonist Imiquimod Is Active against Prions. PLoS One 8(8):e72112.
- Blondel M (2012). Flirting with CFTR modifier genes at happy hour. Genome Med 4: 98.
- Couplan E, Aiyar RS, Kucharczyk R, Kabala A, Ezkurdia N, Gagneur J, St Onge RP, Salin B, Soubigou F, Le Cann M, Steinmetz LM, di Rago JP and Blondel M (2011). A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA 108: 11989-11994
- Marin M and Blondel M (2011). Editorial: In vivo protein folding--at the crossroad between basic research and biotechnology. Biotechnol J 6: 615-617.
- Reis SD, Pang Y, Vishnu N, Voisset C, Galons H, Blondel M and Sanyal S (2011). Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie 93: 1047-1054
- Voisset C, Saupe SJ and Blondel M (2011). The various facets of the protein-folding activity of the ribosome. Biotechnol J 6: 668-673
- Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, Blondel M, Schwarz E and Simonelig M (2011). Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 3: 35-49.
- Gug F, Oumata N, Tribouillard-Tanvier D, Voisset C, Desban N, Bach S, Blondel M, and Galons H (2010). Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography. Bioconjug Chem 21: 279-288
- Kucharczyk R, Ezkurdia N, Couplan E, Procaccio V, Ackerman SH, Blondel M and di Rago JP (2010). Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase. Biochim Biophys Acta 1797: 1105-1112.
- Couplan E, Le Cann M, Le Foll C, Corporeau C, Blondel M and Delarue J (2009). Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system. Biotechnol J 4: 1190-1197
- Kucharczyk R, Zick M, Bietenhader M, Rak M, Couplan E, Blondel M, Caubet SD, and di Rago JP (2009). Mitochondrial ATP synthase disorders: molecular mechanisms and the quest for curative therapeutic approaches. Biochim Biophys Acta 1793: 186-199
- Sasvari Z., Bach S., Blondel M and Nagy PD (2009). Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities. PLoS One 4: e7376
- Voisset C, Saupe S and Blondel M (2009). Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Infectious Diseases, Drug Targets 9: 31-39.
- Fahraeus, R. and Blondel, M. (2008) RNA-assisted protein folding. Biotechnol J, 3, 967-969
- Norez C, Vandebrouck C, Antigny F, Dannhoffer L, Blondel M and Becq F (2008). Guanabenz, an alpha2-selective adrenergic agonist, activates Ca2 -dependent chloride currents in cystic fibrosis human airway epithelial cells. Eur J Pharmacol 592: 33-40
- Tribouillard-Tanvier D, Beringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D and Blondel M. (2008). Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 3: e1981
- Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Beringue V, Sabate R, Kikovska E, Talarek N, Bach S, Huang C, Desban N, Saupe SJ, Supattapone S, Thuret JY, Chedin S, Vilette D, Galons H, Sanyal S and Blondel M (2008). Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 3: e2174
- Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ and Blondel M (2008). Tools for the study of ribosome-borne protein folding activity. Biotechnol J 3: 1033-1040.
- Blondel M and Meijer L (2007). Editorial: role of cyclin-dependent kinase-5 (Cdk5) in the central nervous system. Biotechnol J 2: 914-915
- Guiffant D, Tribouillard D, Gug F, Galons H, Meijer L, Blondel M and Bach S (2007). Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol J 2: 68-75
- Tribouillard D, Gug F, Galons H, Bach S, Saupe SJ and Blondel M (2007). Antiprion drugs as chemical tools to uncover mechanisms of prion propagation. Prion 1: 48-52.
- Bach S, Tribouillard D, Talarek N, Desban N, Gug F, Galons H and Blondel M (2006). A yeast-based assay to isolate drugs active against mammalian prions. Methods 39: 72-77
- Tribouillard D, Bach S, Gug F, Desban N, Beringue V, Andrieu T, Dormont D, Galons H, Laude H, Vilette D and Blondel M (2006). Using budding yeast to screen for anti-prion drugs. Biotechnol J 1: 58-67
- Thuret JY and Blondel M (2006). Ready for an orange revolution in biotechnology? Biotechnol J 1: 237-238
- Bach S, Blondel M and Meijer L (2006). Evaluation of CDK inhibitors selectivity: from affinity chromatography to yeast genetics. Chapter in Enzyme Inhibitors Volume 2 “Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents” Edited by Yue E.W. and Smith P.J. CRC press, 103-119.
- Gug F, Blondel M, Desban N, Bouaziz S, Vierfond JM and Galons H (2005). An expeditious synthesis of 6-aminophenanthridines. Tetrahedron Letters 46: 3725-3727
- Blondel M, Bach S, Bamps S, Dobbelaere J, Wiget P, Longaretti C, Barral Y, Meijer L and Peter M (2005). Degradation of Hof1 by SCFGrr1 is important for actomyosin contraction during cytokinesis in yeast. Embo J 24: 1440-1452.
- Adolph S, Bach S, Blondel M, Cueff A, Moreau M, Pohnert G, Poulet SA, Wichard T, Zuccaro A (2004). Cytotoxicity of diatom-derived oxylipins in organisms belonging to different phyla. J Exp Biol 207: 2935-2946
- Knockaert M, Blondel M, Bach S, Leost M, Elbi C, Hager GL, Nagy SR, Han D, Denison M, Ffrench M, Ryan XP, Magiatis P, Polychronopoulos P, Greengard P, Skaltsounis L and Meijer L (2004). Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the anti-proliferative effects of indirubins. Oncogene 23: 4400-4412
- Gug F, Bach S, Blondel M, Vierfond JM, Martin AS and Galons H (2004) A single step synthesis of 6-aminophenanthridines from anilines and 2-chlorobenzonitriles. Tetrahedron 60: 4705-4708.
- Gstaiger M, Luke B, Hess D, Oakeley EJ, Wirbelauer C, Blondel M, Vigneron M, Peter M and Krek W (2003). Control of Nutrient-Sensitive Transcription Programs by the Unconventional Prefoldin URI. Science 302: 1208-1212
- Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D, Meijer L, Cullin C and Blondel M (2003). Isolation of drugs active against mammalian prions using a yeast-based screening assay . Nat Biotech 21: 1075-1081.
- Blondel M, Galan JM, Chi Y, Lafourcade C, Longaretti C, Deshaies RJ and Peter M (2000). Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. Embo J 19: 6085-6097
- Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F and Krek W (2000). The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. Embo J 19: 5362-5375
- Blondel M, Galan JM and Peter M. (2000). Isolation and characterization of HRT1 using a genetic screen for mutants unable to degrade Gic2p in Saccharomyces cerevisiae. Genetics 155: 1033-1044
- Bouquin N, Barral Y, Courbeyrette R, Blondel M, Snyder M and Mann C (2000). Regulation of cytokinesis by the Elm1 protein kinase in Saccharomyces cerevisiae. J Cell Sci 113: 1435-1445.
- Blondel M, Alepuz PM, Huang LS, Shaham S, Ammerer G and Peter M (1999). Nuclear export of Far1p in response to pheromones requires the export receptor Msn5p/Ste21p. Genes Dev 13: 2284-2300.
- Blondel M and Mann C (1996). G2 cyclins are required for the degradation of G1 cyclins in yeast. Nature 384: 279-282.
